Advertisement

Topics

FDA grants priority review to Merck's Keytruda as treatment for MSI-H cancer

04:25 EST 1 Dec 2016 | SmartBrief

The FDA has accepted Merck's Keytruda, or pembrolizumab, for priority review as a second-line treatment for patients with adv -More

Original Article: FDA grants priority review to Merck's Keytruda as treatment for MSI-H cancer

NEXT ARTICLE

More From BioPortfolio on "FDA grants priority review to Merck's Keytruda as treatment for MSI-H cancer"

Quick Search
Advertisement
 

Relevant Topic

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...